Resource Summary Report

Generated by NIF on Aug 10, 2026

CellMinerCDB

RRID:SCR_025649
Type: Tool

Proper Citation

CellMinerCDB (RRID:SCR_025649)

Resource Information

URL: https://discover.nci.nih.gov/rsconnect/cellminercdb/

Proper Citation: CellMinerCDB (RRID:SCR_025649)

Description: Web application integrating cancer cell line pharmacogenomics. Enables exploration and analysis of cancer cell line pharmacogenomic data across different sources. Focuses on cancer patient-derived human cell line molecular and pharmacological data. CellMinerCDB (v1.2) includes several improvements.

Synonyms: , Cell Miner CDB, CellMiner Cross-Database, CellMinerCDB 1.2

Resource Type: web application, software resource

Defining Citation: PMID:30553813, PMID:30553813

Keywords: integrating cancer cell line pharmacogenomics, exploration and analysis of cancer cell line pharmacogenomic data, exploration and analysis, cancer cell line, pharmacogenomic data

Funding: NIGMS P41 GM103504;
NCI

Availability: Free, Freely available,

Resource Name: CellMinerCDB

Resource ID: SCR_025649

Record Creation Time: 20240824T053240+0000

Record Last Update: 20260808T190728+0000

Ratings and Alerts

No rating or validation information has been found for CellMinerCDB.

No alerts have been found for CellMinerCDB.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Yoo J, et al. (2026) Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer. Signal transduction and targeted therapy, 11(1).

Zeng PYF, et al. (2026) Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer. Cell reports. Medicine, 7(6), 102820.

Xu C, et al. (2025) Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma. Translational lung cancer research, 14(1), 209.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Li C, et al. (2025) Anticancer drug synergy prediction based on CatBoost. PeerJ. Computer science, 11, e2829.

Tabata S, et al. (2025) Context-Specific Metabolic Alterations in HPRT1 Knockout Cells Within a 3D Culture System. Cancer medicine, 14(23), e71452.

Masood MBE, et al. (2025) Integrated pan-cancer analysis revealed therapeutic targets in the ABC transporter protein family. PloS one, 20(5), e0308585.

Gu Y, et al. (2025) HIG-Syn: a hypergraph and interaction-aware multigranularity network for predicting synergistic drug combinations. Bioinformatics (Oxford, England), 41(Supplement_1), i86.

Smith NJ, et al. (2025) Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma. The EMBO journal, 44(1), 1.

Li J, et al. (2025) Protocol for tumor prognostic prediction, molecular stratification, and target discovery using a machine learning-driven approach. STAR protocols, 6(4), 104130.

Mizunuma M, et al. (2024) Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer research communications, 4(8), 2101.

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene, 43(32), 2475.

Small SH, et al. (2024) Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML. Blood neoplasia, 1(4), 100037.

Nakasuka F, et al. (2024) The role of cytidine 5'-triphosphate synthetase 1 in metabolic rewiring during epithelial-to-mesenchymal transition in non-small-cell lung cancer. FEBS open bio, 14(9), 1570.

Baldasici O, et al. (2022) Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients. International journal of molecular sciences, 23(20).

Jo U, et al. (2021) Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular cancer therapeutics, 20(8), 1431.

Chen P, et al. (2021) Aberrant methylation modifications reflect specific drug responses in small cell lung cancer. Genomics, 113(3), 1114.

Yao X, et al. (2020) A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. Scientific reports, 10(1), 15201.